Steven Urbaniak, DO
Neurology · Philadelphia, PANPI 1891774634
Payments from drug & device makers
Across 1,295 payments — averaging $17.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Biogen$1K
- Novartis$1K
- Upsher-smith Laboratories LLC$1K
- Neurocrine Biosciences, Inc.$1K
- EMD Serono, Inc.$1K
- plus $13K from 53 others
What the payments were for
- Consulting fees$1501%
- Speaking & faculty fees$3121%
- Food & beverage$21,79297%
- Education$1151%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$22,368 in reported general payments places this provider in the 75th percentile of 941 neurology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 14 | $238,911 |
| VumerityDiroximel Fumarate | 14 | $121,399 |
| NuplazidPimavanserin Tartrate | 23 | $113,126 |
| IngrezzaValbenazine Tosylate | 13 | $101,172 |
| CopaxoneGlatiramer Acetate | 12 | $68,861 |
| Nurtec OdtRimegepant Sulfate | 43 | $54,918 |
| QuliptaAtogepant | 27 | $35,105 |
| UbrelvyUbrogepant | 15 | $23,926 |
| Emgality PenGalcanezumab-Gnlm | 32 | $22,981 |
| RexultiBrexpiprazole | 16 | $22,108 |
| Aimovig AutoinjectorErenumab-Aooe | 13 | $20,585 |
| AptiomEslicarbazepine Acetate | 12 | $15,006 |
| OngentysOpicapone | 18 | $11,944 |
| Memantine Hcl | 256 | $7,264 |
| Rasagiline Mesylate | 33 | $4,031 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenVumerity | $1,497 | $121,39914 claims |
| Acadia Pharmaceuticals IncNuplazid | $65 | $113,12623 claims |
| Neurocrine Biosciences, Inc.Ingrezza, Ongentys | $1,166 | $113,11631 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $1,054 | $68,86112 claims |
| AbbVieQulipta, Ubrelvy | $2,415 | $59,03142 claims |
| PfizerNurtec Odt | $487 | $54,91843 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $180 | $22,10816 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $386 | $15,00612 claims |
| Upsher-smith Laboratories LLCTopiramate | $1,397 | $47850 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 941 neurology providers in Pennsylvania.
Other neurology in Philadelphia
- Amit Bar-OrPhiladelphia$7.7M
- Thomas LeistPhiladelphia$5.8M
- Lauren ElmanPhiladelphia$3.3M
- David IrwinPhiladelphia$2.5M
- Daniel KremensPhiladelphia$1.9M
- Frances JensenPhiladelphia$1.8M
- Andres Deik Acosta MadiedoPhiladelphia$1.8M
- Michael SperlingPhiladelphia$1.7M
- Sanjeev VaishnaviPhiladelphia$1.6M
- Andrew SiderowfPhiladelphia$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.